Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 4, 2004 - Issue 3
Submit an article Journal homepage
20
Views
2
CrossRef citations to date
0
Altmetric
Review

Cost-effectiveness of cervical cancer screening strategies

James W Henderson Baylor University, Ben Williams Professor in Economics, One Bear Place 98003, Waco, Texas 76798, USA. [email protected]
Pages 287-296 | Published online: 09 Jan 2014

References

  • ACOG Committee on Practice Bulletins — Gynecology. Cervical cytology screening: clinical management guidelines for obstetrician-gynecologists, number 45. Obstet. Gynecol. 102(2), 417–427 (2003).
  • Ferlay J, Bray F, Pisari P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. Version 1.0. IARC Cancer Base No. 5. IARC Press, Lyon, France (2001).
  • Bosch FX, Lorincz A, Munoz N et al The causal relationship between human papillomavirus and cervical cancer. j Clin. Path. 55(4), 244–265 (2002).
  • ••Comprehensive review of key studies linking human papillomavirus (HPV) and cervical cancer.
  • World Health Organization. World Helth Statistics Annual World Health Organization, Geneva, Switzerland (Various years).
  • Vizcaino AP, Moreno V, Bosch FX et al International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int. J. Cancer86, 429–435 (2000).
  • SEER cancer statistics review 1973–1997 Ries LAG, Eisner MP, Kosary CL (Eds). National Cancer Insititue, MD, USA (2000).
  • Mandelblatt J, Schechter C, Fahs M et al Clinical implications of screening for cervical cancer under Medicare. The natural history of cervical cancer in the elderly: what do we know? What do we need to know? J. Obstet. Cynecol 164(2), 644–651 (1991).
  • Dewar MA, Hall K, Perchalski J. Cervical cancer screening: past success and future challenge. Prim. Care 19,589–606 (1992).
  • McCrory DC, Mather DB, Bastian L et al Evaluation of Cervical Cytology. Evidence report/technology assessment 5. Publication No. 99—E010. Agency for Healthcare Policy Research, MD, USA (1999).
  • Vassilakos P, de Marval F, Munoz M et al. Human papillomavirus (HPV) DNA assay as an adjunct to liquid-based Pap test in the diagnostic triage of women with an abnormal Pap smear. Int. J. Cynecol Obstet. 61(1), 45–50 (1998).
  • Slater DN, Milner PC, Radley H. Audit of deaths from cervical cancer — proposal for an essential component of the National Screening Program. J. Clin. Athol 47, 27–28 (1994).
  • Sasieni PD, Cuzick J, Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. BE J. Cancer 73, 1001–1005 (1996).
  • Hutchinson ML, Zahniser DJ, Sherman ME et al Utility of liquid-based cytology for cervical cancer screening: results of a population-based study conducted in a high cervical cancer incidence region of Costa Rica. Cancer Cytopathol 87,48–55 (1999).
  • Bosch FX, Manos MM, Munoz N et al Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer aBscq Study Group. J. Natl Cancer Inst. 87(11), 796–802 (1995).
  • Cuzick J, Szarewski A, Terry G et al Human papillomavirus testing in primary cervical screening. Lancet 345,1533–1536 (1995).
  • Cuzick J, Sasieni P, Davies P et al. Systematic review of the role of human papillomavirus testing within a cervical cancer screening program. Health Technol Assess. 3,1–196 (1999).
  • Ferenczy A, Franco E, Arseneau J et al Diagnostic performance of Hybrid Capture HPV-DNA assay combined with liquid-based cytologic study. Am. J Obstet. Cynecol 175,651–656 (1996).
  • Kulasingam SL, Highes JP, Kiviat NB et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity and frequency of referral. JA1VI4 288(14), 1749–1757 (2002).
  • Solomon D, Davey D, Kurman R et al The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAIVIA 287, 2114–2119 (2002).
  • •Summary report of new terminology reflecting advances in understanding cervical cancer and cervical screening technology.
  • Munoz N, Bosch FX. HPV and cervical neoplasia. In: The Epidemiology of Cervical Cancer and Human Papillomavims. Munoz N, Boach FX, Shah KV, Meheus A (Eds). Oxford University Press, Oxford, UK, 251–261 (1992).
  • Fahs MC, Plichta SB, Mandelblatt JS. Cost-effective policies for cervical cancer screening: an international review. PharmacoEconomics9(3), 211–230 (1996).
  • ••Review of the state of knowledge as of themid-1990s on the epidemiology of cervical cancer and the cost-effectiveness of the screening options.
  • Saslow D, Runowicz CD, Solomon D et al American Cancer Society guidelines for the early detection of cervical neoplasia and cancer. CA Qincrj Clin.52(6), 342–362 (2002).
  • Cervical cancer screening. ACOG practice bulletin 45. Obstet. Cynecol 102(2), 417–427 (2003).
  • Eaker ED, Vierkant RA, Konitzer KA, Remington PL. Cervical cancer screening among women with and without hysterectomies. Obstet. Cynecol 91, 551–555 (1998).
  • Fox J, Remington P, Layde P, Klein G. The effect of hysterectomy on the risk of an abnormal screening Papanicolaou test result. Am. J Obstet. Cynecol 180(5), 1104–1109 (1999).
  • US Preventive Services Task Force. Screening for cervical cancer: recommendations and rationale. AHRQ publication number 03-515A. Agency for Healthcare Research and Quality. Washington DC, USA, 1–9 (2003).
  • Centers for Disease Control and Prevention. CDC recommendations regarding selective conditions regarding women's health. Morbid. Mortalit. Weekly Rep. 49(RR-2), 35–56 (2000).
  • Sawaya, GF, McConnell KJ, Kulasingam SL et al Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl. J. Med. 349, 1501–1509 (2003).
  • ••Important evidence on the excess risk of cervical cancer associated with less frequent screening.
  • Linos A, Riza E. Comparisons of cervical cancer screening programmes in the European Union. Eur. J. Cancer 36, 2260–2265 (2000).
  • •Summarizes the similarities and differences in the cervical cancer screening programs of the 15 European Union countries.
  • McCrory DC, Matchar DB, Bastian L et al. Evaluation of cervical cytology. Evidence Report/Technology Assessment 5. Prepared by Duke University under contract 290-97-0014. AHCPR publication number 99—E010. Agency for Healthcare Policy and Research, MD, USA (1999).
  • Sherlaw-Johnson C. Gallivan S. Jenkins D. Evaluating cervical cancer screening programmes for developing countries. int. Cancer72, 210–216 (1997).
  • Van Oortmarssen GJ, Habbema JDE Epidemiological evidence for age-dependent regression of preinvasive cervical cancer. Br. J. Cancer 64,559–565 (1991).
  • Holowaty P, Miller AB, To T Natural history of dysplasia of the uterine cervix. J. Natl Cancer Inst. 91,252–258 (1999).
  • Fahey MT, Irwig L, Macaskill P Meta- analysis of Pap test accuracy. Am J. Epidemiol 141,680–689 (1995).
  • Brown AD, Garber AM. Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou results. JAIVIA 281,347–353 (1999).
  • ••Compares cost-effectiveness of the Pap testwith three newer technologies.
  • Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA. The costs, clinical benefits and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann. Intern. Med. 130,97–107 (1999).
  • Eddy DM. Screening for cervical cancer. Ann. Intern. Med. 113,214–226 (1990).
  • •One of the first studies to calculate incremental cost—effectieness ratios (ICERs) in evaluating the effectiveness of various screening strategies.
  • Schneider A. Zahm DM, Kirchmayr R, Schneider VL. Screening for cervical intraepithelial neoplasia grade 2/3: validity of cytologic study, cervicography and human papillomavirus detection. Am. J. Obstet. Cyneco.1174, 1534–1541 (1996).
  • SEER Cancer incidence public-use database. National Cancer Institute, MD, USA (various years).
  • Mandelblatt JS, Lawrence WE Womack SM et al Benefits and costs of using HPV testing to screen for cervical cancer. JAIVIA 287(13), 2372–2381 (2002).
  • •• Comprehensive analysis of cost-effectiveness of screening for cervical cancer with the HPV test in combination with the traditional Pap.
  • Maxwell GL, Carlson JW, Ochoa M et al Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries. Obstet. Cynecol 100(4), 740–748 (2002).
  • van Ballegooijen M, van den Akker-van Marle ME, Patnick, J et al. Overview of important cervical cancer screening process values in European Union (EU) countries and tentative predictions of the corresponding effectiveness and cost-effectiveness. Eur Cancer 36(17), 2177–2188 (2000).
  • Gyrd-Hansen D. Holund B, Andersen P. A cost-effectiveness analysis of cervical cancer screening: health policy implications. Health Pol. 34,35–51 (1995).
  • Takenaga N, Kai I, Ohi G. Evaluation of three cervical cancer detection programs in Japan with special reference to cost—benefit analysis. Cancer55, 2514–2519 (1985).
  • Matsunaga G, Tsuji I, Sato S et al Cost-effectiveness analysis of mass screening for cervical cancer in Japan. J. Epidemiol 7,135–141 (1997).
  • van der Akker-van Marle ME, van Ballegooijen M, van Oortmarssen GJ et al Cost-effectiveness of cervical cancer screening: comparison of screening policies. Natl Cancer Inst. 94 (3), 193–204 (2002).
  • van Ballegooijen M, Koopmanschap MA, Habbema JD. The management of cervical intraepithelial neoplasia (CIN): extensiveness and costs in The Netherlands. Eur. J. Cancer 31A, 1672–1676 (1995).
  • van Ballegooijen M, Habbema JD, van Oortmarssen GJ et al Preventive Pap smears: balancing costs, risks and benefits. Br. Cancer65, 930 (1992).
  • Van den Akker-Van Marle ME, Ballegooijen M, Van Oortmarssen GJ et al Cost-effectiveness of cervical cancer screening: comparison of screening policies. J. Natl Cancer Inst. 94,193–204 (2002).
  • Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAIVIA 290(6), 781–789 (2003).
  • Goldie SJ, Freedberg KA, Weinstein MC et al Cost-effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Am. J. Med.111 (ER2), 140–149 (2001).
  • Kim JJ, Wright TC, Goldie, SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAIVIA 287(18), 2382–2390 (2002).
  • •Study examining cost-effectiveness of follow-up and treatment strategies of women diagnosed with atypical squarnous cells of undetermined significance (ASCUS).
  • Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA. The costs, clinical benefits and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann. Intern. Med. 130, 97–107 (1999).
  • •Study examining the cost-effectiveness of using the HPV test in a modified screening strategy for HIV-infected women.
  • Goldie SJ, Kuntz KM. Modeling compliance in cost-effectiveness analyses of screening programs. Med. Decis. Making 20,529 (2001).
  • Carter PM, Coburn TC, Luszczak M. Cost-effectiveness of cervical cytologic examination during pregnancy. J. Am Roan] Pam. Pract. 6,537–45 (1993).
  • Mandelblatt JS, Lawrence WF, Gaffikin L et al Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. J. Natl Cancer Inst. 94,1469–1483 (2002).
  • •Good example of cost-effective screening options in a low-resource setting.
  • Goldie S, Kuhn L, Denny L et al Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAIVIA 285(24), 3107–3115 (2001).
  • Suba EJ, Hung NC, Due NB, Raab SS. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the socialist republic of Vietnam. Cancer 91, 928–929 (2001).
  • CUZiCk J. Human papillomavirus testing for primary cervical cancer screening. JAIVIA 283,108–109 (2000).
  • Cuzick J, Sasieni P. Estimates of the cost impact of introducing HPV testing into a cervical screening programme. In: New Developments in Cervical Cancer Screening and Prevention. Franco E, Monsonego I (Eds). Blackwell Science Ltd, Oxford, UK, 364–372 (1999).
  • Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Eng. I Med. 348,489–490 (2003).
  • Hildesheim A, Hadjimichael O, Schwartz PE et al Risk factors for rapid-onset cervical cancer. Am J. Obstet. Cynecol 180, 571–577 (1999).
  • Janerich DT, Hadjimichael O, Schwartz PE et al The screening histories of women with invasive cervical cancer, Connecticut. Am.Public Health 85,791–794 (1995).
  • Carozzi F, Ronco G, Confortini M et al Prediction of high-grade cervical intraepithelial neoplasia in cytologically normal women by human papillomavirus testing. Br. Cancer 83 (11), 1462–1467 (2000).
  • Schiffman MET, Herrero R. Hildesheim A et al HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAIVIA 283, 87–93 (2000).
  • Josefsson AM, Magnusson PK, Ylitalo N et al. Viral load of human papillomavirus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 355,2189–2193 (2000).
  • Franceschi S, Herrero R, La Vecchia C. Cervical cancer screening in Europe: what next? Eui:j Cancer 36,2272–2275 (2000).
  • •Call for Europeans to remain at the cutting-edge in making screening options available in the future.
  • Plummer P, Herrero R. Potential impact of HPV vaccines: epidemiological perspectives. Abstract No. 127, Proceeding of the 18th International Papillomavims Conference. Barcelona, Spain, 164 (2000).

Websites

  • US Vital Statistics, 2001. National Center for Health Statistics, MD, USA www.cdc.govinchsinvss.htm (Accessed May 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.